Q2 EPS Forecast for Kyverna Therapeutics Lowered by Analyst

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Equities researchers at HC Wainwright lowered their Q2 2026 earnings per share estimates for Kyverna Therapeutics in a research report issued on Friday, May 15th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($0.69) per share for the quarter, down from their prior estimate of ($0.65). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($2.74) per share. HC Wainwright also issued estimates for Kyverna Therapeutics’ Q3 2026 earnings at ($0.78) EPS, Q4 2026 earnings at ($0.85) EPS, FY2026 earnings at ($2.98) EPS, Q1 2027 earnings at ($0.85) EPS, Q2 2027 earnings at ($0.79) EPS, Q3 2027 earnings at ($0.79) EPS, Q4 2027 earnings at ($0.58) EPS and FY2027 earnings at ($3.01) EPS.

A number of other equities research analysts have also recently commented on KYTX. JPMorgan Chase & Co. reduced their price objective on Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, May 13th. Wall Street Zen raised Kyverna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Friday, March 27th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $30.00.

Kyverna Therapeutics Trading Down 10.0%

Shares of Kyverna Therapeutics stock opened at $8.54 on Tuesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 8.15 and a current ratio of 8.15. Kyverna Therapeutics has a 52 week low of $2.06 and a 52 week high of $13.67. The stock has a 50 day moving average price of $9.05 and a two-hundred day moving average price of $8.39. The stock has a market capitalization of $519.15 million, a PE ratio of -2.60 and a beta of 2.05.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its earnings results on Tuesday, May 12th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.09.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. AIGH Capital Management LLC lifted its holdings in shares of Kyverna Therapeutics by 33.3% in the first quarter. AIGH Capital Management LLC now owns 2,000,000 shares of the company’s stock valued at $17,260,000 after purchasing an additional 500,000 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Kyverna Therapeutics by 16.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,762,617 shares of the company’s stock worth $16,569,000 after purchasing an additional 250,418 shares in the last quarter. Adage Capital Partners GP L.L.C. purchased a new stake in Kyverna Therapeutics in the 4th quarter valued at about $15,667,000. Vanguard Group Inc. increased its stake in Kyverna Therapeutics by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 1,322,625 shares of the company’s stock valued at $7,936,000 after buying an additional 9,858 shares during the last quarter. Finally, Balyasny Asset Management L.P. purchased a new position in shares of Kyverna Therapeutics in the 4th quarter worth approximately $9,220,000. Institutional investors own 18.08% of the company’s stock.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.